Validation of the immune-module in an independent prospective European cohort, analyzed 12 months after adalimumab initiation, shows that the frequency of SIRPα/β+memory B cells was significantly lower (< 9.4%) in ADA+ compared to ADA− RA patients. The gene discussed is ADA; the disease is rheumatoid arthritis.